Cellectis S.A. (CMVLF)
USD 1.25
(0.0%)
USD 1.25
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 18 Thousand USD | -208.37% |
| 2022 | 17.39 Million USD | -53.82% |
| 2021 | 37.67 Million USD | 0.0% |
| 2020 | 37.67 Million USD | 891.94% |
| 2019 | 3.79 Million USD | -61.99% |
| 2018 | 9.99 Million USD | -55.72% |
| 2017 | 22.56 Million USD | -44.82% |
| 2016 | 40.89 Million USD | -21.86% |
| 2015 | 52.33 Million USD | 131.5% |
| 2014 | 22.6 Million USD | 2.91% |
| 2013 | 21.96 Million USD | -14.8% |
| 2012 | 25.78 Million USD | 47.61% |
| 2011 | 17.46 Million USD | -8.34% |
| 2010 | 19.05 Million USD | 27.11% |
| 2009 | 14.99 Million USD | 13.35% |
| 2008 | 13.22 Million USD | 404.03% |
| 2007 | 2.62 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -40.76 Thousand USD | 99.22% |
| 2024 Q2 | 3.31 Million USD | 8235.98% |
| 2023 Q1 | -195 Thousand USD | -101.27% |
| 2023 Q3 | -26 Thousand USD | -121.14% |
| 2023 Q4 | -5.19 Million USD | -19874.04% |
| 2023 Q2 | 123 Thousand USD | 163.08% |
| 2023 FY | -18.85 Million USD | -208.37% |
| 2022 Q4 | 15.33 Million USD | 10322.67% |
| 2022 Q1 | 1.31 Million USD | 126.27% |
| 2022 Q2 | 1.01 Million USD | -22.33% |
| 2022 Q3 | -150 Thousand USD | -114.72% |
| 2022 FY | 17.39 Million USD | -53.82% |
| 2021 Q4 | -4.99 Million USD | -453.77% |
| 2021 Q1 | 17.45 Million USD | 449.47% |
| 2021 FY | 37.67 Million USD | 0.0% |
| 2021 Q2 | -579 Thousand USD | -103.32% |
| 2021 Q3 | -902 Thousand USD | -55.79% |
| 2020 Q1 | 45.52 Million USD | 3804.56% |
| 2020 FY | 37.67 Million USD | 891.94% |
| 2020 Q2 | -2.92 Million USD | -106.43% |
| 2020 Q3 | -1.64 Million USD | 43.97% |
| 2020 Q4 | -4.99 Million USD | -204.57% |
| 2019 Q4 | -1.22 Million USD | -129.04% |
| 2019 Q3 | 4.23 Million USD | 1155.79% |
| 2019 FY | 3.79 Million USD | -61.99% |
| 2019 Q2 | 337 Thousand USD | -24.94% |
| 2019 Q1 | 449 Thousand USD | 81.05% |
| 2018 Q4 | 248 Thousand USD | 570.27% |
| 2018 FY | 9.99 Million USD | -55.72% |
| 2018 Q3 | 37 Thousand USD | -99.18% |
| 2018 Q2 | 4.49 Million USD | -17.78% |
| 2018 Q1 | 5.46 Million USD | 12.78% |
| 2017 FY | 22.56 Million USD | -44.82% |
| 2017 Q1 | 6.14 Million USD | -16.81% |
| 2017 Q2 | 6.16 Million USD | 0.28% |
| 2017 Q3 | 5.55 Million USD | -9.94% |
| 2017 Q4 | 4.84 Million USD | -12.8% |
| 2016 Q4 | 7.39 Million USD | -32.63% |
| 2016 FY | 40.89 Million USD | -21.86% |
| 2016 Q2 | 17.27 Million USD | 132.93% |
| 2016 Q1 | 7.41 Million USD | -73.57% |
| 2016 Q3 | 10.97 Million USD | -36.5% |
| 2015 Q1 | 8.66 Million USD | -1.59% |
| 2015 Q4 | 28.06 Million USD | 243.26% |
| 2015 FY | 52.33 Million USD | 131.5% |
| 2015 Q3 | 8.17 Million USD | 5.09% |
| 2015 Q2 | 7.77 Million USD | -10.21% |
| 2014 FY | 22.6 Million USD | 2.91% |
| 2014 Q4 | 8.8 Million USD | -4.09% |
| 2014 Q3 | 9.18 Million USD | 51.2% |
| 2014 Q2 | 6.07 Million USD | -0.64% |
| 2014 Q1 | 6.11 Million USD | 19.64% |
| 2013 Q2 | 3.09 Million USD | 1.46% |
| 2013 FY | 21.96 Million USD | -14.8% |
| 2013 Q1 | 3.05 Million USD | 0.0% |
| 2013 Q3 | 5.01 Million USD | 62.12% |
| 2013 Q4 | 5.1 Million USD | 1.75% |
| 2012 FY | 25.78 Million USD | 47.61% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | 17.46 Million USD | -8.34% |
| 2010 FY | 19.05 Million USD | 27.11% |
| 2009 FY | 14.99 Million USD | 13.35% |
| 2008 FY | 13.22 Million USD | 404.03% |
| 2007 FY | 2.62 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 838.007% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.846% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 105.634% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.985% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.07% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 137.299% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 114.487% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.88% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -480.271% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 99.816% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 72.614% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 152.709% |
| Mesoblast Limited | -35.16 Million USD | 100.051% |
| Marizyme, Inc. | 457.7 Thousand USD | 96.067% |
| Genus plc | 178.7 Million USD | 99.99% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.992% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 71.073% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 95.612% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 263.636% |
| ContraFect Corporation | -154 Thousand USD | 111.688% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 136.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 76.551% |
| IMV Inc. | -962.29 Thousand USD | 101.871% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 104.645% |
| MultiCell Technologies, Inc. | 49.32 USD | -36396.35% |
| ONE Bio Corp. | 20.12 Million USD | 99.911% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.955% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 63.19% |
| Q BioMed Inc. | -8988.00 USD | 300.267% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.936% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 216.701% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.959% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 101.577% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 74.286% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 463.489% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 87.189% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 118.459% |
| GB Sciences, Inc. | -624.00 USD | 2984.615% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 120.923% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 8753.846% |
| Enzolytics Inc. | 30.7 Thousand USD | 41.383% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 96.269% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.998% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 103.498% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 97.084% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.996% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 303.252% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 121.467% |
| Kadimastem Ltd | -630.13 Thousand USD | 102.857% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 98.178% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 99.813% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.883% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 252.091% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 89.805% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 89.805% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 98.674% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 162.069% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 96.0% |
| SYBLEU INC | 11.69 Thousand USD | -53.899% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 99.609% |
| Bioxytran, Inc. | -8285.00 USD | 317.26% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 104.826% |
| Neutra Corp. | 14.33 Thousand USD | -25.567% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 121.951% |
| PureTech Health plc | -1.6 Million USD | 101.123% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 101.798% |
| IXICO plc | 3.27 Million USD | 99.45% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 102.594% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 101.005% |
| CSL Limited | 7.7 Billion USD | 100.0% |